Articles
- Articles Featured HighlightsImmunomic Therapeutics' article titled, "LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition," has been published in FrontiersRead more
GEN magazine spotlight, “Expansion of the RNA Technology Universe”
Articles HighlightsImmunomic Therapeutics' Prakash Koodathingal, Director of RNA Therapeutics Development, shares his insight into CQAs for saRNA for GEN magazine's "Expansion of the RNA Technology Universe." Read the full article here:Read moreWashington Business Journal interviews CEO, Dr. William Hearl
Articles Featured Highlights PressJuly 14, 2023 Immunomic Therapeutics is highlighted in Washington Business Journal's cover story, “Life sciences funding is tough, but there are still avenues to money.” WBJ talks about how aRead moreHow Jimmy Carter Boosted a Life-saving Cancer Drug, Washington Post
ArticlesIn the Washington Post article "How Jimmy Carter boosted a life-saving cancer drug," our scientific advisor Dr. Drew Pardoll provides his outlook on Carter's impact on immune therapy. Pardoll, theRead moreCellular Cancer Immunotherapy Development and Manufacturing in the Clinic, Dr. Duane Mitchell
ArticlesThe article "Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic," authored by our academic collaborator, Dr. Duane Mitchell was released in AACR's journal of Clinical Cancer Research on MarchRead moreBioBuzz Interview with Brian Stamper, ITI’s VP of Cell Therapy
Articles Blog Featured Highlights Presshttps://biobuzz.io/brian-stamper-appointed-vice-president-cell-therapy-operations-at-immunomic-therapeutics/Read moreITI Highlighted as Life Sciences Leader in Montgomery County, MD
Articles Blog PressImmunomic Therapeutics highlighted in Washington Business Journal as a life sciences leader in Maryland’s Montgomery County: The Immunology Capital Next to the Nation’s Capital. Click here to read more: http://ow.ly/NQrc50IVzkTRead moreOncology Tube Interview: ITI-3000 First-In-Human Trial for Merkel Cell Carcinoma
Articles Blog Featured PressClaire Rosean, Senior Scientist discusses ITI-3000, First-In-Human Trial for Merkel Cell Carcinoma and the preclinical data presented at AACR. Click below to watch the full interview: https://www.oncologytube.com/video/40935/claire-rosean-phd-immunomix-uw-aacr22-mcc-iti-3000-first-in-human-trial?channelName=AACRRead moreExclusive: Rockville biotech expanding, ‘on the prowl’ for talent ahead of planned IPO
Articles PressRead the latest Washington Business Journal article highlighting Immunomic Therapeutics by clicking the link below: https://www.bizjournals.com/washington/news/2022/03/17/immunomic-therapeutics-expanding-hiring-pre-ipo.htmlRead moreMaryland’s Immunomic Therapeutics Exceeds Fundraising Goal, Envisions Future IPO
Articles FeaturedImmunomic Therapeutics Incorporated (ITI), located in Rockville, Maryland recently announced it had closed on $61.3M in financing, exceeding its initial fundraising projections by over $11M. The Korean investment group HLB Co., LTD ledRead moreBill Hearl Interview with Rich Bendis’ BioTalk after completing a new $61.3 million raise
ArticlesBill Hearl joins BioTalk host Rich Bendis to discuss their recent successes in funding, research, and their growth in the BioHealth Capital Region Dr. William Hearl is the founder ofRead moreThe Use and Misuse of Cancer Life Expectancy Statistics
Articles Blog Featured HighlightsPlease read the article authored by ITI titled, “The Use and Misuse of Cancer Life Expectancy Statistics” which explores how GBM patients adjust and deal with dire life expectancy statistics.Read more